scispace - formally typeset
B

Bandaru S. Reddy

Researcher at Rutgers University

Publications -  277
Citations -  28225

Bandaru S. Reddy is an academic researcher from Rutgers University. The author has contributed to research in topics: Azoxymethane & Colorectal cancer. The author has an hindex of 97, co-authored 277 publications receiving 27634 citations. Previous affiliations of Bandaru S. Reddy include Pharmacia & Dana Corporation.

Papers
More filters
Journal ArticleDOI

Chemoprophylaxis of colon cancer.

TL;DR: Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal anti-inflammatory drugs, particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents, however, several of these chemopreventive agents induce side effects at effective high dose levels.
Journal Article

Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.

TL;DR: AOM-induced ODC and TPK activities were significantly suppressed by dietary DFMO progressively at all stages of colon carcinogenesis, indicating the plausibility of using these enzymes as intermediate biochemical markers of colon cancer.
Journal ArticleDOI

Effects of combination of calcium and aspirin on azoxymethane-induced aberrant crypt foci formation in the colons of mice and rats.

TL;DR: The results indicate that the combination of calcium and aspirin did not produce a synergistic effect on the ACF formation in AOM-treated mice and rats.
Journal ArticleDOI

Modulation of inducible nitric oxide synthase expression in rat intestinal cells by colon tumor promoters.

TL;DR: The data suggest a possible role of colon tumor promoters, DAG and DC, for iNOS over-expression through activation of the PKC pathway in an in vitro system using the rat intestinal cell line, RIE-1.
Journal ArticleDOI

Chemoprophylaxis of colon cancer

TL;DR: Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal antiinflammatory drugs, particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents, however, several of these chemopreventive agents induce side effects at effective high dose levels.